Education
About Us
Working with TipRanks
Follow Us
Instil Bio (TIL)
NASDAQ:TIL
TIL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.62 - $92.00
Previous CloseN/A
Volume80.17K
Average Volume (3M)86.34K
Market Cap
$113.29M
Enterprise Value$403.02M
Total Cash (Recent Filing)$8.80M
Total Debt (Recent Filing)$86.89M
Price to Earnings (P/E)―
Beta6.75
Next Earnings
May 08, 2025EPS Estimate
-2.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.39
Shares Outstanding6,525,887
10 Day Avg. Volume77,576
30 Day Avg. Volume86,338
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)27.36
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market Cap3.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.42
Forecast
1Y Price Target
$81.00Price Target Upside375.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Instil Bio News
PremiumCompany Announcements
Instil Bio Reports 2024 Financial Results and Outlook
PremiumStock Analysis & Ideas
Jefferies Predicts Up to ~500% Jump for These 2 ‘Strong Buy’ Stocks
PremiumCompany Announcements
Instil Bio Secures Loan to Refinance Facility---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe SYN-2510 1L NSCLC chemo combo trial has begun dosing with plans to escalate and enroll around 60 patients by the end of the year, indicating progress in clinical trials.
Financial StabilityInstil Bio is sufficiently capitalized with $112.5MM through upcoming key milestones, which supports its financial stability.
Milestone PaymentInstil Bio is expected to submit an IND for SYN-2510 in the U.S., potentially triggering a $10MM milestone payment.
Bears Say
Competitive PressureInstil appears to be losing ground to multiple new assets that are expected to submit INDs by YE25.
Delayed U.S. TrialsFor the second time, Instil has pushed out the initiation of the U.S. trial evaluating AXN-2510 in combo with chemo as a treatment for 1L NSCLC to YE25.
Valuation ConcernsRecent acquisitions by major companies highlight a valuation gap for Instil, suggesting it is undervalued.
---
TIL FAQ
What was Instil Bio’s price range in the past 12 months?
Instil Bio lowest stock price was $9.62 and its highest was $92.00 in the past 12 months.
What is Instil Bio’s market cap?
Instil Bio’s market cap is $113.29M.
When is Instil Bio’s upcoming earnings report date?
Instil Bio’s upcoming earnings report date is May 08, 2025 which is in 35 days.
How were Instil Bio’s earnings last quarter?
Instil Bio released its earnings results on Mar 04, 2025. The company reported -$1.82 earnings per share for the quarter, beating the consensus estimate of -$3.22 by $1.4.
Is Instil Bio overvalued?
According to Wall Street analysts Instil Bio’s price is currently Undervalued.
Does Instil Bio pay dividends?
Instil Bio does not currently pay dividends.
What is Instil Bio’s EPS estimate?
Instil Bio’s EPS estimate is -2.59.
How many shares outstanding does Instil Bio have?
Instil Bio has 6,525,887 shares outstanding.
What happened to Instil Bio’s price movement after its last earnings report?
Instil Bio reported an EPS of -$1.82 in its last earnings report, beating expectations of -$3.22. Following the earnings report the stock price went down -4.267%.
Which hedge fund is a major shareholder of Instil Bio?
Currently, no hedge funds are holding shares in TIL
---
Instil Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$81.00 (375.91% Upside)
$81.00 (375.91% Upside)
Blogger Sentiment
Bullish
TIL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 345.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
60.74%
12-Months-Change
Fundamentals
Return on Equity
-37.51%
Trailing 12-Months
Asset Growth
-18.69%
Trailing 12-Months
Company Description
Instil Bio
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
---
TIL Stock 12 Month Forecast
Average Price Target
$81.00
▲(375.91% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering TIL
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+40.65%
reiterated a buy rating last month
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +40.65% per trade.
---